Evaluation of serum progesterone level on third day after intrauterine insemination on pregnancy outcomes in two routes of luteal phase support in women with unexplained infertility : A randomized clinical trial study.

Evaluation of serum progesterone level on third day after IUI on pregnancy outcomes in two methods of luteal phase support in women with unexplained infertility

One-blind clinical trial with random assignment to the intervention group (receiving Crinone vaginal gel) and control (receiving Duphaston), the third phase of the trial on 70 infertile patients, randomization before the start of the study with Random allocation software function, IUI, assessment of pregnancy outcomes at the end of the study

On IUI day, all patients are randomly divided into two groups: intervention: receiving 90 mg / once daily vaginal crinone gel 8% , control group: receiving Duphaston 10 mg twice daily (oral form of progesterone) in all Patients continue to support the luteal phase until pregnancy testing, 14 days after IUI. Serum progesterone levels are measured in all patients 72 hours after IUI and pregnancy outcomes including biochemical pregnancy, clinical pregnancy, ongoing pregnancy, abortion in each patient are evaluated and the relationship between serum progesterone levels on the third day after IUI and these outcomes in each patient will be examined.

General admission requirements: Age range 18-37 IUI cycles Patients with normal uterine cavity Exclusion criteria: Patients with uterine problems such as fibroids; anatomical problems of the uterus, polyps; salpingitis Patients with a history of recurrent miscarriage RIF patients Age over 37 years Patients with grade 3 or 4 endometriosis Body mass index higher than 30 kg / m2 Patients with endometrial thickness less than 7 mm per day trigger

A: receiving 90 mg / once daily vaginal crinone gel 8%) B: receiving Duphaston aston 10 mg twice daily (oral form of progesterone)

Biochemical pregnancy, Clinical Pregnancy, abortion

In order to randomly allocate the samples to each of the study groups, Random allocation software was used, which generated a random sequence using a single block method. The address of the software is as follows: https://random-allocation-software.software.informer.com/2.0/. How to randomize: This software according to the uniform statistical distribution of discrete sequence in the form of letters (or numerical) in the form of ... ABAABAABABBA produces that each letter belongs to a group to hide In order to hide the random allocation so that the assigned group is not known before the individual is assigned, each of the random sequences created is recorded on a card and the cards are placed in the envelopes , respectively. At the beginning of the registration of participants, based on the order of entry of eligible participants into the study, one of the envelopes is opened in order and the assigned group of the participant is revealed. How to use the software by installing the software file and after opening it, first the number of groups is determined, then the sample size of each group and finally the method of numerical or letter randomization is selected in a simple or block form. In this study, the method A block was selected.

This research is a one-blind study. Thus, the person analyzing the results is unaware of the status of allocation in groups. R

The data will be presented in the article after analysis

2022

Academic researchers and obstetricians

Clinical application in patients undergoing IUI

Paper corresponding author

E-mail to corresponding author